ABSTRACT
Although catheter-based radiofrequency ablation is no longer experimental, it is not yet the first-line treatment for most patients. The authors describe how this procedure works, its indications, benefits, and limitations, and important points to communicate to potential candidates for this procedure.
Footnotes
↵a Dr. Lewis has disclosed that he has received consulting fees and honoraria from the Medtronic company for teaching and speaking.
↵b Dr. Schweikert has disclosed that he has received honoraria from the Boston Scientific, Glaxo SmithKline, Biosense Webster, Medtronic, and St. Jude Medical companies for teaching and speaking.
↵c Dr. Cummings has disclosed that she has received honoraria from Boston Scientific for speaking and from Corazon Consulting for consulting.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.